Latest Boehringer Ingelheim Stories
BONN, Germany, October 14, 2014 /PRNewswire/ -- Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer
RIDGEFIELD, Conn., Oct.
Case Funding Company says recent $650MM settlement of approximately 4K filed cases in both state and federal courts over blood thinner, amounts to an average Pradaxa settlement amount or settlement
As Pradaxa Lawsuit Claims Continue Boehringer Ingelheim Conducts Clinical Trials On Idarucizumab, A Potential Reversal Agent To Pradaxa Columbus, OH (PRWEB)
New Executive Brings Experience from Merck, Boehringer Ingelheim, and Proctor & Gamble PLYMOUTH MEETING, Pa., Sept. 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
RIDGEFIELD, Conn., Sept. 26, 2014 /PRNewswire/ - Boehringer Ingelheim applauds the U.S.
Approval Marks New Inhaler Choice for tiotropium RIDGEFIELD, Conn., Sept. 25, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S.
LifeScienceIndustryResearch.com adds “Spiriva (Asthma) – Forecast and Market Analysis to 2023” to its store.
- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany,
The Nation’s Premier Annual Physical Activity and Hispanic Family Health Celebration Boehringer Ingelheim Pharmaceuticals, Inc.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.